Pharmacokinetic-Directed High-Dose Busulfan Combined with Cyclophosphamide and Etoposide Results in Predictable Drug Levels and Durable Long-Term Survival in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation-Reference-Cited by-同舟云学术

Pharmacokinetic-Directed High-Dose Busulfan Combined with Cyclophosphamide and Etoposide Results in Predictable Drug Levels and Durable Long-Term Survival in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Published:2012-08 Issue:8 Volume:18 Page:1287-1294
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Zhang Hongzheng,Graiser Michael,Hutcherson Donald A.,Dada M. Olufemi,McMillan Stephanie,Ali Zahir,Flowers Christopher R.,Waller Edmund K.

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference23 articles.

1. Busulfan in hematopoietic stem cell transplantation;Ciurea;Biol Blood Marrow Transplant,2009

2. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule;Madden;Biol Blood Marrow Transplant,2007

3. Hematopoietic stem-cell transplantation;Copelan;N Engl J Med,2006

4. A detailed analysis of charges for hematopoietic stem cell transplantation at a children’s hospital;Kline;Bone Marrow Transplant,1998

5. Treatment strategies in follicular lymphomas: current status and future perspectives;Hiddemann;J Clin Oncol,2005

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute Myeloid Leukaemia in Children;The EBMT Handbook;2024

2. Determination of Busulfan and Melphalan in Plasma by Turbulent Flow Chromatography-Tandem Mass Spectrometry;Methods in Molecular Biology;2023-12-01

3. Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma;Annals of Hematology;2020-02-05

4. Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation;Biology of Blood and Marrow Transplantation;2020-02

5. Costs and Outcomes with Once-Daily versus Every-6-Hour Intravenous Busulfan in Allogeneic Hematopoietic Cell Transplantation;Biology of Blood and Marrow Transplantation;2020-01